All In Biotech

Drug Trial Radar · NCT07328529

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Safety, Tolerability, and Efficacy of SRX246, a Vasopressin 1a Receptor Antagonist, in Aggressive Participants With Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Azevan PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Congressionally Directed Medical Research Programs
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug SRX246 works to treat irritability, agitation, aggression and self-injury (IAAS) behaviors in adult males with Fragile X Syndrome (FXS). It will also learn about the safety of drug SRX246. The main questions it aims to answer are: * Does drug SRX246 lower the number of times participants experience IAAS behaviors? * What medical problems do participants have when taking drug SRX246? Researchers will compare drug SRX246 to a placebo (a look-alike substance that contains no drug) to see if drug SRX246 works to treat IAAS behaviors. Participants will: * Take drug SRX246 or a placebo every day for up to 8 months * Have weekly checkups by phone or video to answer study questions * Have periodically scheduled home visits by nurses to conduct medical check-ups and tests * Keep a diary of their symptoms

Conditions

  • Aggressive Behavior in Fragile X Syndome

Interventions

  • SRX246Drug

    SRX246 120mg capsules for oral administration

  • PlaceboDrug

    Placebo capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Aberrant Behavior ChecklistTime frame: Over an 8 month period

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis, MIND Institute

    Sacramento, California

  • Rush University Medical Center

    Chicago, Illinois

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.